Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD by Messchendorp, A.L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/209004
 
 
 
Please be advised that this information was generated on 2019-12-04 and may be subject to
change.
REFERENCES
1. Simmonds HA, Van Acker KJ, Cameron JS, Snedden W. The
identiﬁcation of 2,8-dihydroxyadenine, a new component of
urinary stones. Biochem J. 1976;157:485–487.
2. Runolfsdottir HL, Palsson R, Agustsdottir IM, et al. Kidney
disease in adenine phosphoribosyltransferase deﬁciency. Am
J Kidney Dis. 2016;67:431–438.
3. Bollée G, Dollinger C, Boutaud L, et al. Phenotype and geno-
type characterization of adenine phosphoribosyltransferase
deﬁciency. J Am Soc Nephrol. 2010;21:679–688.
4. Zaidan M, Palsson R, Meriequ E, et al. Recurrent 2,8-
dihydroxyadenine nephropathy: a rare but preventable
cause of renal allograft failure. Am J Transplant. 2014;14:
2623–2632.
5. Bollée G, Harambat J, Bensman A, et al. Adenine phosphor-
ibosyltransferase deﬁciency. Clin J Am Soc Nephrol. 2012;7:
1521–1527.
6. Nanmoku K, Kurwosawa A, Shinzato T, et al. Febuxostat for the
preventionof recurrent 2,8-dihydroxyadenine nephropathy due
to adenine phosphoribosyltransferase deﬁciency following
kidney transplantation. Intern Med. 2017;56:1387–1391.
7. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney
Meeting Report: revised diagnostic criteria for chronic active T
cell–mediated rejection, antibody-mediated rejection, and
prospects for integrative endpoints for next-generation clinical
trials. Am J Transplant. 2017;18:293–307.
8. Nasr SH, Sethi S, Cornell LD, et al. Crystalline nephropathy due
to 2,8-dihydroxyadeninuria: an under-recognized cause of
irreversible renal failure. Nephrol Dial Transplant. 2010;25:
1909–1915.
9. Deng L, Yang M, Frund S, et al. 2,8-Dihydroxyadenine uro-
lithiasis in a patient with considerable residual adenine phos-
phoribosyltransferase activity in cell extracts but with
mutations in both copies of APRT. Mol Genet Metabol.
2001;72:260–264.
Effect of a Somatostatin Analogue
on the Vasopressin Pathway in Patients
With ADPKD
A. Lianne Messchendorp1, Bart J. Kramers1, Edwin M. Spithoven1, Katrin Stade2,
Esther Meijer1 and Ron T. Gansevoort1; on behalf of the DIPAK-1 Study Investigators3
1Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and
2BRAHMS GmbH, Hennigsdorf, Germany
Correspondence: Ron T. Gansevoort, University Medical Center Groningen, Division of Nephrology, Expertise Center for
Polycystic Kidney Diseases, PO 30.001, 9700 RB, Groningen, The Netherlands. E-mail: R.T.Gansevoort@umcg.nl
3Principal investigators of the DIPAK-1 Study are Joost P.H. Drenth, Johan W. de Fijter, Ron T. Gansevoort, Esther Meijer,
Folkert W. Visser, Jack F.M. Wetzels and Robert Zietse.
Received 20 December 2018; revised 1 April 2019; accepted 29 April 2019; published online 16 May 2019
Kidney Int Rep (2019) 4, 1170–1174; https://doi.org/10.1016/j.ekir.2019.04.027
ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A utosomal dominant polycystic kidney disease(ADPKD) is characterized by high activity of
adenylyl cyclase (AC) in renal tubular cells, which
stimulates the conversion of adenosine triphosphate
(ATP) into cyclic adenosine monophosphate (cAMP).
This results in high intracellular cAMP levels, which
lead to aberrant renal tubular epithelial cell prolifer-
ation and chloride-driven ﬂuid excretion in the kid-
ney, causing cyst formation and growth. Ultimately
these processes lead to kidney failure, with a need
for renal replacement therapy such as dialysis or renal
transplantation.
The vasopressin V2 receptor antagonist tolvaptan
has the ability to inhibit the activity of AC and to lower
cAMP levels. Tolvaptan can therefore attenuate kidney
growth and the rate of renal function decline.
However, the effect of tolvaptan is limited to the kid-
ney, and its aquaretic side effects hamper widespread
clinical use. Therefore there is still an unmet need for
new therapies to slow disease progression in ADPKD.
In this respect, somatostatin analogues are of interest,
as somatostatin analogues also have the ability to lower
intracellular cAMP levels by inhibiting the activity of
AC in kidney as well as liver tissue. These drugs
decrease the growth rates of liver and kidney volume
in ADPKD.15
Because both drugs lower cAMP levels by inhib-
iting the activity of AC, it may be that there is a
pharmacodynamic interaction between somatostatin
analogues and tolvaptan. Interestingly, older experi-
mental studies have suggested involvement of so-
matostatin in renal water handling, causing either a
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diuretic or an antidiuretic effect, dependent on
vasopressin levels.69 A more recent study observed a
lower urine volume in PKD1 mice receiving a com-
bination of a somatostatin analogue and tolvaptan in
comparison to mice receiving tolvaptan alone.10 This
suggests that there indeed may be an interaction be-
tween the somatostatin and vasopressin pathways.
In this study, we therefore investigated whether the
somatostatin analogue lanreotide has an effect on
vasopressin levels and renal water handling in patients
with ADPKD. The Materials and Methods section can
be found in the Supplementary Material.
RESULTS
Subject Characteristics
A total of 305 patients were included, 53.4% of whom
were female. The estimated glomerular ﬁltration rate
(eGFR) was 50  11 ml/min per 1.73 m2 and the height-
adjusted total kidney volume (htTKV) 1089 (7541670)
ml/m. There were no differences in baseline charac-
teristics between patients randomized to standard care
(n ¼ 152) or lanreotide (n ¼ 153) (Table 1).
Parameters of Aquaresis in Patients Receiving
Lanreotide or Standard Care
At baseline, there were no statistically signiﬁcant dif-
ferences in 24-hour urine volume, free water clearance
(FWC), fractional free water clearance (FFWC), plasma
osmolality, urine osmolality, sodium excretion, osmol
excretion, and copeptin between patients randomized
to standard care or lanreotide (Table 1).
From baseline to week 12, there were no statistically
signiﬁcant differences in change in parameters of
aquaresis, between patients receiving standard care or
lanreotide (Table 2). Total osmol excretion in the 2
groups was similar at baseline (903  299 vs. 867 
225 mOsm/24-hour, P ¼ 0.3) and after 12 weeks (882 
262 vs. 845  253 mOsm/24-hour, P ¼ 0.2), and also
change in osmolar excretion at 12 weeks was not
different between both groups (23  242 vs. 36 
202 mOsm/24-hour, P ¼ 0.6).
Subgroups With Possible Differences in
Aquaresis
The association of copeptin with change in 24-hour
urine volume or FFWC was not statistically signiﬁ-
cant different between patients receiving standard care
or lanreotide (interaction term: baseline copeptin*-
treatment group, P ¼ 0.77 and P ¼ 0.67, respectively).
The association of use of diuretics with change in
24-hour volume or FFWC was also not statistically
signiﬁcant different between the 2 study groups
(interaction term: use of diuretics*treatment group,
P ¼ 0.84 and P ¼ 0.97 respectively). The association
Table 1. Baseline characteristics
Characteristic
Standard care
(n [ 152)
Somatostatin
analogue (n [ 153)
Female, n (%) 81 (53.3) 82 (53.6)
Age, yr 48.5  7.22 48.2  7.41
BMI, kg/m2 27.1  4.9 26.9  4.5
SBP, mm Hg 133  14 132  13
DBP, mm Hg 82  10 82  9
AHT, n (%) 137 (90.1) 140 (91.5)
RAASi, n (%) 126 (82.9) 125 (81.7)
Diuretics, n (%) 60 (39.5) 57 (37.3)
eGFR, ml/min per 1.73 m2 50  11 51  12
htTKV, ml/m 1028 (720–1678) 1138 (779–1723)
PKD mutation, n (%)
PKD1 truncating 64 (42.1) 76 (49.7)
PKD1 nontruncating 41 (27.0) 33 (21.6)
PKD2 30 (19.7) 30 (19.6)
No mutation detected 7 (4.6) 8 (5.2)
Missing 10 (6.6) 6 (3.9)
Urine volume, L/24 h 2.44  0.84 2.28  0.69
FWC, L/24 h –0.68  1.00 –0.72  0.77
FFWC, % –1.28  2.26 –1.52  1.60
Plasma osmolality, mOsm/kg 288  5.79 289  5.57
Urine osmolality, mOsm/kg 389  116 401  117
Sodium excretion, mmol/24 h 170  73.7 156  56.6
Osmol excretion, mOsm/24 h 903  299 867  225
Plasma copeptin, pmol/l 9.6 (5.8–14.7) 9.9 (5.5–18.5)
AHT, anti-hypertensive therapy; BSA, body surface area; DBP, diastolic blood pressure;
eGFR, estimated glomerular ﬁltration rate; htTKV, height-adjusted total kidney volume;
PKD, polycystic kidney disease; RAASi, RAAS inhibitors; SBP, systolic blood pressure.
Variables are presented as mean  SD, or as median (interquartile range) in the case of
nonnormal distribution. P values are calculated using independent-sample t-test in case
of normal distribution, Mann–Whitney U in case of nonnormal distribution, and c2 in
case of categorical data.
Table 2. Change in parameters of aquaresis from baseline to week 12 in patients receiving lanreotide versus standard care
Variable Standard care
Somatostatin
analogue
Mean difference
(95% CI) P
Change urine volume (L/24 h) 0.071  0.70 –0.020  0.63 –0.09 (–0.25 to 0.06) 0.25
Change FWC (L/24 h) 0.16  0.77 0.09  0.64 –0.08 (–0.25 to 0.09) 0.39
Change FFWC (%) 0.25  1.73 0.20  1.32 –0.05 (–0.42 to 0.32) 0.79
Change plasma osmolality (mOsm/kg) –0.32  4.91 0.77  5.09 1.09 (–0.08 to 2.26) 0.07
Change urine osmolality (mOsm/kg) –22.1  98.5 –9.99  98.5 12.1 (–10.8 to 35.1) 0.30
Change sodium excretion (mmol/24 h) –12.0  73.0 –7.64  59.1 4.3 (–11.2 to 19.8) 0.58
Change osmol excretion (mOsm/24 h) –23  242 –36  202 26.7 (–64.9 to 40.2) 0.64
Change plasma copeptin (pmol/l) –0.07  5.58 –0.93  13.5 –0.86 (–3.23 to 1.52) 0.48
eGFR, estimated glomerular ﬁltration rate; FFWC, fractional free water clearance; FWC, free water clearance.
Data are expressed as mean  SD. Differences between groups were tested with an independent-sample t-test.
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between baseline eGFR and change in FFWC was
signiﬁcantly different between patients receiving
standard care or lanreotide (interaction term: baseline
eGFR*treatment group, P ¼ 0.001). In patients
receiving lanreotide, there was a signiﬁcant negative
association between eGFR and change in FFWC (Stan-
dardized [St.] b ¼ 0.24, B ¼ 0.03, 95% conﬁdence
interval [CI] ¼ 0.05 to 0.009, P ¼ 0.005), whereas
in patients receiving standard care there was a sig-
niﬁcant positive association (St. b ¼ 0.18, B ¼ 0.03,
95% CI ¼ 0.002–0.06, P ¼ 0.01) (Supplementary
Figure S1). The difference in association between
baseline eGFR and change in 24-hour urine volume did
not reach statistical signiﬁcance (interaction term:
baseline eGFR*treatment group, P ¼ 0.08).
When patients were divided according to the mean
eGFR of the study population (eGFR # or >50 ml/min
per 1.73 m2), we observed no differences in change in
parameters of aquaresis in patients with an eGFR #50
ml/min per 1.73 m2. However, patients with an eGFR
>50 ml/min per 1.73 m2 had a relative decrease in FWC
with lanreotide compared to patients receiving stan-
dard care (lanreotide 0.04  0.74 L/24 hours, control
0.28  0.75 L/24 hours, difference P ¼ 0.01) as well as
in FFWC (lanreotide 0.16  0.24%, control 0.48 
1.34%, difference P ¼ 0.005). The 24-hour urine vol-
ume and copeptin levels also decreased in patients
receiving lanreotide compared to standard care,
although this did not reach formal statistical signiﬁ-
cance (lanreotide 0.05  0.73 L/24-hour, control
0.15  0.71 L/24-hour, difference P ¼ 0.10 and
lanreotide 2.86  15.5, control 0.32  3.8 pmol/L,
difference P ¼ 0.12) (Table 3 and Figure 1).
In line with the results of the above interaction tests,
there were no differences in parameters of aquaresis
when patients were studied stratiﬁed according to
Table 3. Change in parameters of aquaresis from baseline to week 12 in patients receiving lanreotide versus standard care stratiﬁed according
to eGFR
Variable
eGFR £ 50 ml/min per 1.73 m2 eGFR > 50 ml/min per 1.73 m2
Standard care
Somatostatin
analogue
Mean difference
(95% CI) P Standard care
Somatostatin
analogue
Mean difference
(95% CI) P
Number (n) 67 80 – 85 73 –
Change urine volume (L/24 h) –0.04  0.68 0.00  0.54 0.04 (–0.17 to 0.24) 0.72 0.15  0.71 –0.05  0.73 –0.20 (–0.43 to 0.04) 0.10
Change FWC (L/24 h) 0.01  0.78 0.19  0.52 0.18 (–0.04 to 0.41) 0.11 0.28  0.75 –0.04  0.74 –0.32 (–0.57 to –0.07) 0.01
Change FFWC (%) –0.06  2.11 0.49  1.32 0.55 (–0.08 to 1.18) 0.09 0.48  1.34 –0.16  0.24 –0.64 (–1.09 to –0.20) 0.005
Change plasma osmolality (mOsm/kg) –0.21  5.39 0.89  5.31 1.10 (–0.71 to 2.91) 0.23 –0.41  4.54 0.62  4.88 0.78 (–0.50 to 2.57) 0.18
Change urine osmolality (mOsm/kg) –6.5  90.9 –17.0  66.8 –10.5 (–37.0 to 16.0) 0.43 –34.4  103.0 –1.9  125.5 32.5 (–4.82 to 69.9) 0.09
Change sodium excretion (mmol/24 h) –14.3  72.8 –13.4  57.7 11.0 (–20.9 to 22.6) 0.94 –10.1  73.6 –0.7  60.5 9.46 (–13.1 to 32.0) 0.41
Change osmol excretion (mOsm/24 h) 0.02  268 –54.9  188 –55.0 (–135.0 to 25.0) 0.18 –42.1  219 –12.8  217 29.3 (–43.7 to 102.3) 0.43
Change plasma copeptin (pmol/l) 0.24  7.20 0.86  11.02 0.62 (–2.54 to 3.78) 0.70 –0.32  3.8 –2.86  15.5 –2.53 (–6.05 to 0.99) 0.12
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; FFWC, fractional free water clearance; FWC, free water clearance.
Data are expressed as mean  SD. Differences between groups were tested with an independent-sample t-test. Bold P values indicate statistical significance.
Figure 1. Change in 24-hour urine volume (left panel) and fractional free water clearance (right panel) from baseline to T12 in patients receiving
standard care or lanreotide, stratiﬁed according to mean level of estimated glomerular ﬁltration rate (eGFR) at baseline.
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median copeptin level or whether or not they used
diuretics (Supplementary Table S1).
DISCUSSION
In this post hoc analysis of the DIPAK-1 trial, we
investigated the possible interaction between the so-
matostatin and vasopressin pathways on aquaresis.
Overall, there were no differences in change in 24-hour
urine volume, FWC, FFWC, or copeptin levels in pa-
tients with ADPKD receiving 12 weeks of standard care
or the somatostatin analogue lanreotide. However, an
interaction with baseline eGFR was found, indicating
that patients with more preserved kidney function who
received lanreotide had a decrease in FWC and FFWC.
Both the somatostatin and the vasopressin V2 re-
ceptors co-localize with AC in the basolateral membrane
in renal tubular cells of the collecting duct. Nine
distinct membrane-bound AC isoforms (AC19) have
been identiﬁed, and each can exert unique effects in
various cell types of the kidney.S1 It is currently un-
known whether there are speciﬁc AC isoforms associ-
ated with the vasopressin V2 or somatostatin receptor.
If both receptors interact with the same AC isoform, an
effect of the somatostatin analogue on renal water
handling may be expected. The ﬁrst studies that pro-
posed the involvement of somatostatin in renal water
handling were performed in dogs that had a high
vasopressin level. These studies showed a diuretic effect
after infusion of somatostatin.6,S2 In contrast, a study by
Walker et al. found that intravenous infusion of so-
matostatin in water-loaded human subjects caused an
antidiuretic effect.7 In addition, these investigators
showed that vasopressin levels remained stable in these
subjects, concluding that somatostatin has a direct ef-
fect on the renal tubule with respect to renal water
handling. Based on these data and the aforementioned
experimental data, Walker et al. hypothesized that the
effects of somatostatin may be dependent on levels of
vasopressin; that is, with high levels of vasopressin,
somatostatin elicits a diuretic effect, and with low levels
of vasopressin an antidiuretic effect. This hypothesis
was tested by another study group in 1993. They found
in rats that the effect was not dependent on vasopressin
but rather on somatostatin levels. A low dose of so-
matostatin had a diuretic and a high dose of somato-
statin an antidiuretic effect in the presence or absence of
vasopressin.S3 Studies with subcutaneous administra-
tion of somatostatin analogues, which is essentially a
high dose of somatostatin, did indeed show an antidi-
uretic effect of this drug in experimental studies.10,S4,S5
In our study, we did not observe an effect of the so-
matostatin analogue lanreotide on aquaresis in patients
with ADPKD overall. An explanation for not ﬁnding an
effect of lanreotide on the vasopressin pathway could be
that this effect was dependent on the characteristics of
the included patients. As reasoned above, the effect of
somatostatin on aquaresis could be dependent on vaso-
pressin, with lanreotide not having an effect in in-
dividuals with higher vasopressin, as is often the case in
ADPKD.S6 Furthermore, in previous studies, only
healthy subjects were studied who did not use medica-
tion that may affect aquaresis. The effect of somatostatin
analogues on aquaresis may become less apparent with
more severe ADPKD, when tubular function is
compromised and urine concentrating defects exist,S7,S8
or when diuretics are used. We therefore tested whether
there was an interaction between the effect on aquaresis
of treatment and baseline copeptin, eGFR, or use of di-
uretics. We found no such interaction for baseline
copeptin or use of diuretics. We did, however, observe
an interaction for the association of baseline eGFR with
treatment-induced change in FFWC and a nearly sig-
niﬁcant interaction with change in 24-hour urine vol-
ume. When patients were stratiﬁed according to mean
eGFR, there was a decrease in FWC and FFWC with
lanreotide in patients with an eGFR>50 ml/min per 1.73
m2, whereas aquaresis remained stable with lanreotide in
subjects with impaired kidney function. No statistically
signiﬁcant differences in 24-hour urine volume were
observed. These ﬁndings suggest that in ADPKD pa-
tients with a more preserved kidney function, lanreotide
has an effect on renal water handling, albeit small.
The ﬁrst studies that investigated the therapeutic ef-
fect of somatostatin analogues in ADPKD were under-
powered and too short in duration to allow ﬁrm
conclusions on the renoprotective effect of these
drugs.14 A recent larger clinical trial, with balanced
baseline characteristics, showed no effect on rate of eGFR
loss,S9 but did show a beneﬁcial effect on growth rate of
kidney as well as liver volume. Therefore, there may be a
place for somatostatin analogues in the treatment of
ADPKD patients with symptoms related to an increased
intra-abdominal volume. Combination therapy of tol-
vaptan with a somatostatin analogue may therefore be
indicated in such patients. An interaction between the
somatostatin and vasopressin pathways could have
consequences for the renoprotective effect of tolvaptan
as well as its aquaretic side effects when tolvaptan and a
somatostatin analogue are used simultaneously. In our
study, the decrease in FFWC and FWC that we observed
in subjects with preserved renal function seems to be a
direct effect of lanreotide and not mediated by vaso-
pressin, as copeptin levels (as surrogate of vasopressin)
did not change. If anything, copeptin levels decreased in
this patient group, whereas an increase might have been
expected if the effect of lanreotide was mediated by
vasopressin. Therefore, there may be a possibility that
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vasopressin V2 receptor antagonist and somatostatin
analogues have synergistic effects in the treatment of
ADPKD. Although the anti-aquaretic effect of lanreotide
in our study was small and did not lead to a signiﬁcant
effect on 24-hour urine volume, it may havemore impact
in a situation in which there is excessive free water
clearance, as with tolvaptan use. Combination therapy
with a somatostatin analogue and tolvaptan may there-
fore not only result in an additive effect on total kidney
volume growth in ADPKD, but may also reduce the
aquaretic side effects of tolvaptan. Future studies should
investigate this hypothesis.
Our study had limitations. First, our study was open
label, and therefore patients in the lanreotide and control
group may have adhered differently to dietary recom-
mendations concerning water and osmole intake. How-
ever, we did not observe differences in change in
parameters of aquaresis and osmolar excretion in the
overall group of patients, indicating that it would not have
affected our results to a large extent. Second, we included
patients with later-stage ADPKD, assessed as an eGFR
between 30 and 60 ml/min per 1.73 m2, and found an
interaction between the effects of lanreotide on aquaresis
and baseline kidney function. We cannot exclude, there-
fore, that stronger effects would be seen in subjects with
an eGFR above the inclusion criteria of the present study.
In conclusion, we found that the somatostatin
analogue lanreotide may lower free water clearance, but
only in ADPKD patients with a relatively preserved
kidney function.We hypothesize that when somatostatin
analogues are added to tolvaptan for volume reduction in
ADPKD, a decrease in polyuria may be expected in pa-
tients with preserved kidney function. Whether such an
effect is clinically relevant remains to be studied.
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